CA-HILLSTONE-NETWORKS
7.6.2022 08:02:11 CEST | Business Wire | Press release
Hillstone Networks , a leading provider of innovative and accessible cybersecurity solutions, today announced the global availability of their simplified portfolio that delivers on cyber resilience, securing critical assets against sophisticated, multifaceted cyberattacks and an expanding attack surface.
Today’s workforce and workloads require flexibility, quality of service, and above all, protection. Security solutions need to be equally flexible and deliver on enterprise-grade cyber resilience. The Hillstone Networks solutions have evolved from a network security platform, included in the Gartner Magic Quadrant for Enterprise Firewalls for 8 consecutive years, into a robust portfolio that delivers on cyber resilience, from edge to cloud, and everything in between, to over 23,000 customers worldwide.
At RSAC 2022, in San Francisco, Hillstone will showcase its broad range of solutions across these initiatives:
- SD-WAN : Hillstone Secure SD-WAN secures today’s borderless networks with granular visibility and enforcement into all interactions across all entry points into the network, with the ability to drill further into user, device, and access behavior.
- ZTNA : Hillstone ZTNA solution secures remote access for today’s work-from-anywhere deployments, or heavily regulated industries with sensitive data that need to secure their evolving edge perimeter. Fine-grained access controls allow for precise enforcement of privileges from wherever it’s needed.
- Microsegmentation : Hillstone CloudHive protects cloud-native and cloud-based apps, for dev/ops teams who rely on app portability and microservices, and cloud service providers where multi-tenancy can be risky without segmenting or isolating network access. Support for both VMware and OpenStack provide cross-platform portability across clouds.
- CWPP : Hillstone CloudArmour protects cloud applications running in public or multiple cloud environments, integrating into existing CI/CD and DevOps environments and processes with full application stack visibility. Protect bare metal hosts, virtual machines, containers, and serverless workloads.
- NDR : Hillstone sBDS delivers continuous network monitoring with an AI-driven network detection and response platform that collects and aggregates network traffic data, applying behavioral analysis and AI/ML, and delivering insights to security teams from a single view.
- XDR : Hillstone iSource rolls up all the key activities including threat detection, investigation, response, and real-time threat hunting into a single platform and get extensive visibility across all relevant threat data from device endpoints, applications, networks, and security devices, including 3rd party devices.
“Cyber-resiliency is the infrastructure’s ability to weather a storm of relentless attacks and bounce quickly back. Cyber-resilient infrastructure transforms traditional security, which is inflexible, static, and impractical, into a modernized and agile security plan that’s adaptive, dynamic, and realistic. This is the Hillstone vision and reflected in the solutions we deliver to the market,” states Tim Liu, CTO and co-founder, Hillstone Networks.
"Today's typical IT infrastructure environment is highly disaggregated in nature and presents complex challenges with respect to security. I believe Hillstone Networks delivers a suite of AI/ML enhanced cybersecurity solutions that are designed to provide visibility, ease of deployment, and simplify ongoing management through integration into existing SecOps frameworks," states Will Townsend, Vice President & Principal Analyst, Networking & Security Practices, Moor Insights & Strategy.
About Hillstone Networks
Hillstone Networks' innovative and accessible cybersecurity solutions reshape enterprise security, enabling cyber resilience while lowering TCO. By providing comprehensive visibility, superior intelligence, and rapid protection to see, understand, and act against multilayer, multistage cyberthreats, Hillstone is favorably rated by leading analysts and trusted by global companies. To learn more visit www.hillstonenet.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005278/en/
Link:
Social Media:
https://www.facebook.com/Hillstone-Networks-230976560386832/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom